JWCA
RNAM

J.W. Cole Advisors’s Avidity Biosciences RNAM Stock Holding History

J.W. Cole Advisors’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-31,292
Closed -$283K – 914
2023
Q4 		$283K Buy
+31,292
New +$209K 0.02% 671

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

J.W. Cole Advisors's RNAM Position: Q1 2024 in Review

J.W. Cole Advisors sold out of Avidity Biosciences (RNAM) in Q1 2024, closing a stake of 31,292 shares — an estimated $283K sold.

J.W. Cole Advisors first reported a position in RNAM in Q4 2023 and held it in 1 quarter. The position peaked at $283K in Q4 2023. 158 funds tracked by Wall St. Rank hold RNAM as of Q1 2024.

  • J.W. Cole Advisors reported no remaining Avidity Biosciences position as of Q1 2024 after selling out during the quarter.
  • J.W. Cole Advisors sold 31,292 Avidity Biosciences shares in Q1 2024, an estimated $283K.
  • J.W. Cole Advisors first reported a position in Avidity Biosciences in Q4 2023 and held it in 1 quarter.
  • J.W. Cole Advisors's Avidity Biosciences position peaked at $283K in Q4 2023.
  • 158 funds tracked by Wall St. Rank held Avidity Biosciences as of Q1 2024.

Based on J.W. Cole Advisors's 13F filing for Q1 2024, filed 30 Apr 2024.